ST-100, a novel dry eye treatment, achieved positive topline results in a phase 2 clinical trial, according to a press release from Stuart Therapeutics.
In the multicenter, randomized, controlled, double-masked trial, 160 patients received twice-daily dosing of 20 mg/mL of ST-100, 50 mg/mL of ST-100 or placebo.
The 50 mg/mL group achieved the study’s primary endpoint of Schirmer’s test responder rate at 28 days (P = .0266). The therapy also demonstrated improvement in several symptoms and ocular staining scores as early as day 7, as well as improvement in overall (Read more...)